CR20120283A - Inhibidor de bromodominio de benzodiazepina - Google Patents
Inhibidor de bromodominio de benzodiazepinaInfo
- Publication number
- CR20120283A CR20120283A CR20120283A CR20120283A CR20120283A CR 20120283 A CR20120283 A CR 20120283A CR 20120283 A CR20120283 A CR 20120283A CR 20120283 A CR20120283 A CR 20120283A CR 20120283 A CR20120283 A CR 20120283A
- Authority
- CR
- Costa Rica
- Prior art keywords
- bromodominium
- benzodiazepina
- inhibitor
- compound
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un compuesto de benzodiazepina de la fórmula (I), a procesos para su preparación, a composiciones farmacéuticas que contienen este compuesto, y a su uso en terapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0919433A GB0919433D0 (en) | 2009-11-05 | 2009-11-05 | Novel compounds |
GBGB1010509.6A GB201010509D0 (en) | 2010-06-22 | 2010-06-22 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120283A true CR20120283A (es) | 2012-08-14 |
Family
ID=42667965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120283A CR20120283A (es) | 2009-11-05 | 2012-05-28 | Inhibidor de bromodominio de benzodiazepina |
Country Status (32)
Country | Link |
---|---|
US (3) | US9023842B2 (es) |
EP (3) | EP2722334B1 (es) |
JP (1) | JP5524343B2 (es) |
KR (1) | KR101424989B1 (es) |
CN (1) | CN102762569B (es) |
AU (1) | AU2010314395B2 (es) |
BR (1) | BR112012010706A2 (es) |
CA (1) | CA2779355C (es) |
CL (1) | CL2012001178A1 (es) |
CO (1) | CO6540003A2 (es) |
CR (1) | CR20120283A (es) |
CY (2) | CY1114988T1 (es) |
DK (2) | DK2722334T3 (es) |
DO (1) | DOP2012000114A (es) |
EA (1) | EA020390B1 (es) |
ES (3) | ES2652304T3 (es) |
HK (3) | HK1191012A1 (es) |
HR (2) | HRP20140107T1 (es) |
HU (1) | HUE026421T2 (es) |
IL (2) | IL219090A0 (es) |
MA (1) | MA33803B1 (es) |
ME (1) | ME02360B (es) |
MX (1) | MX2012005295A (es) |
MY (1) | MY160456A (es) |
NZ (1) | NZ599258A (es) |
PE (1) | PE20121181A1 (es) |
PL (2) | PL2496580T3 (es) |
PT (2) | PT2496580E (es) |
RS (2) | RS54592B1 (es) |
SI (2) | SI2496580T1 (es) |
SM (2) | SMT201400024B (es) |
WO (1) | WO2011054553A1 (es) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME02356B (me) * | 2009-11-05 | 2016-06-20 | Glaxosmithkline Llc | Inhibitor bromodomena benzodiazepina |
GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
MX362384B (es) | 2010-05-14 | 2019-01-15 | Dana Farber Cancer Inst Inc | Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
CA2799381A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
MX2014012635A (es) | 2012-04-20 | 2015-05-15 | Abbvie Inc | Derivados de isoindolona. |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
AU2012382373A1 (en) | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
EP2885286B1 (de) | 2012-08-16 | 2017-03-22 | Bayer Pharma Aktiengesellschaft | 2,3-benzodiazepine |
EP2884983B1 (en) * | 2012-08-16 | 2017-10-04 | GlaxoSmithKline LLC | Benzodiazepines for treating small cell lung cancer |
CA2886125A1 (en) | 2012-09-28 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Bet protein-inhibiting 5-aryl triazole azepines |
US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
CA2902225A1 (en) * | 2013-02-28 | 2014-09-04 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
WO2014164780A1 (en) | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Fused tetracyclic bromodomain inhibitors |
US9050346B2 (en) | 2013-03-11 | 2015-06-09 | Abbvie Inc. | Bromodomain inhibitors |
EP2970323B1 (en) | 2013-03-14 | 2017-10-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Furopyridines as bromodomain inhibitors. |
CN105407894A (zh) | 2013-03-14 | 2016-03-16 | 康威基内有限公司 | 用于抑制含布罗莫结构域的蛋白质的方法和组合物 |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
EP3581576B1 (en) | 2013-03-15 | 2022-01-26 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor |
EP2792355A1 (en) | 2013-04-17 | 2014-10-22 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
JP6388915B2 (ja) | 2013-04-26 | 2018-09-12 | ベイジーン,リミテッド | 置換5−(3,5−ジメチルイソオキサゾール−4−イル)インドリン−2−オン |
JP6461121B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | 新規の二環式ブロモドメイン阻害剤 |
ES2661437T3 (es) | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio |
AR096758A1 (es) * | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
CN105849110B (zh) | 2013-11-08 | 2019-08-02 | 达纳-法伯癌症研究所有限公司 | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
GB201320994D0 (en) * | 2013-11-28 | 2014-01-15 | Univ Dundee | Enzyme function probes |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
BR112016017045A2 (pt) | 2014-01-31 | 2017-08-08 | Dana Farber Cancer Inst Inc | Derivados de diazepano e usos dos mesmos |
KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
WO2015120393A1 (en) * | 2014-02-10 | 2015-08-13 | Concert Pharmaceuticals, Inc. | Substituted triazolobenzodiazepines |
WO2015120476A1 (en) * | 2014-02-10 | 2015-08-13 | Salk Institute For Biological Studies | Increasing storage of vitamin a, vitamin d and/or lipids |
WO2015121230A1 (de) * | 2014-02-14 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | 9-substituierte 2,3-benzodiazepine |
JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス,インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
PL3129378T3 (pl) | 2014-04-09 | 2020-03-31 | Kainos Medicine, Inc. | Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu |
SG10201809353TA (en) | 2014-04-23 | 2018-11-29 | Incyte Corp | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS |
LT3157928T (lt) | 2014-06-20 | 2019-05-27 | Constellation Pharmaceuticals, Inc. | 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos |
NO2719005T3 (es) | 2014-07-28 | 2018-01-20 | ||
ES2896400T3 (es) * | 2014-08-01 | 2022-02-24 | Nuevolution As | Compuestos activos frente a bromdominios |
EP3177626A4 (en) | 2014-08-08 | 2017-12-27 | Dana Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
BR112017002190A2 (pt) | 2014-08-08 | 2017-11-21 | Dana Farber Cancer Inst Inc | derivados de di-hidropteridinona e usos dos mesmos |
JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Betタンパク質阻害剤として用いるための三環式複素環化合物 |
JP2017530155A (ja) * | 2014-10-02 | 2017-10-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 化合物 |
KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
JP2017537166A (ja) * | 2014-12-05 | 2017-12-14 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤 |
WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
EP3253756B1 (en) | 2015-02-03 | 2021-09-22 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
KR20180035785A (ko) | 2015-06-26 | 2018-04-06 | 텐샤 세러퓨틱스 인코포레이티드 | Nut 중간선 암종의 치료 |
JP6765622B2 (ja) | 2015-07-17 | 2020-10-07 | 日本光電工業株式会社 | 救命支援装置 |
EP3347021A4 (en) | 2015-09-11 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | CYANO-THIENOTRIAZOLOAZEPINES AND THEIR USES |
JP2018526424A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 |
CN108289957A (zh) * | 2015-10-02 | 2018-07-17 | 达纳-法伯癌症研究所股份有限公司 | 溴区结构域抑制剂和检查点阻断的组合疗法 |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
HUE050217T2 (hu) | 2016-04-15 | 2020-11-30 | Abbvie Inc | Brómdomén inhibitorok |
KR102643344B1 (ko) | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
ES2937307T3 (es) | 2016-07-26 | 2023-03-27 | Univ Southern California | Inhibición selectiva del bromodominio del BDF1 fúngico |
WO2018086605A1 (zh) | 2016-11-10 | 2018-05-17 | 山东罗欣药业集团股份有限公司 | 一种含氮大环类化合物、其制备方法、药物组合物及应用 |
JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン |
CN107759607B (zh) * | 2017-11-29 | 2019-08-23 | 上海万巷制药有限公司 | 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法 |
US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
JP2023532233A (ja) | 2020-06-23 | 2023-07-27 | ジェネンテック, インコーポレイテッド | 大環状化合物及びその使用方法 |
GB202016977D0 (en) | 2020-10-26 | 2020-12-09 | In4Derm Ltd | Compounds |
CN115427407B (zh) | 2020-12-01 | 2024-02-27 | 成都苑东生物制药股份有限公司 | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 |
GB2621505B (en) | 2021-06-29 | 2024-07-03 | Tay Therapeutics Ltd | Pyrrolopyridone derivatives useful in the treatment of inflammatory disorders, immune disorders and cancer |
AU2023255396A1 (en) | 2022-04-19 | 2024-10-24 | Nuevolution A/S | Compounds active towards bromodomains |
WO2024018423A1 (en) | 2022-07-21 | 2024-01-25 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3610848A1 (de) * | 1986-04-01 | 1987-10-15 | Boehringer Ingelheim Kg | Neue 1,4-diazepine |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
KR100255493B1 (ko) | 1991-10-11 | 2000-08-01 | 가마쿠라 아키오 | 골조송증 치료제 |
JPH06128257A (ja) | 1992-10-13 | 1994-05-10 | Yoshitomi Pharmaceut Ind Ltd | ピリドジアゼピン化合物 |
WO1995014694A1 (en) | 1993-11-22 | 1995-06-01 | Merck & Co., Inc. | Benzodiazepines |
IT1285567B1 (it) | 1996-02-21 | 1998-06-18 | Alfa Chem Ital | Nuovo processo per la sintesi del nabumetone |
WO1997047622A1 (fr) | 1996-06-12 | 1997-12-18 | Japan Tobacco Inc. | Inhibiteurs de production de cytokines, composes triazepine et intermediaires correspondants |
PT989131E (pt) | 1996-09-13 | 2003-03-31 | Mitsubishi Pharma Corp | Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais |
JPH11228576A (ja) * | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
ES2388434T3 (es) | 2003-11-03 | 2012-10-15 | Glaxo Group Limited | Dispositivo de administración de fluido |
SG115845A1 (en) | 2004-03-31 | 2005-10-28 | Univ Singapore | Modulation of trip-br function and method of treating proliferative disorders |
GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMOR AGENT |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
-
2010
- 2010-08-06 RS RS20160102A patent/RS54592B1/en unknown
- 2010-08-06 MY MYPI2012001967A patent/MY160456A/en unknown
- 2010-08-06 SI SI201030514T patent/SI2496580T1/sl unknown
- 2010-08-06 EP EP13192666.9A patent/EP2722334B1/en active Active
- 2010-08-06 HU HUE13192666A patent/HUE026421T2/en unknown
- 2010-08-06 PL PL10740654T patent/PL2496580T3/pl unknown
- 2010-08-06 EA EA201290183A patent/EA020390B1/ru not_active IP Right Cessation
- 2010-08-06 EP EP10740654.8A patent/EP2496580B1/en active Active
- 2010-08-06 SI SI201031117T patent/SI2722334T1/sl unknown
- 2010-08-06 CN CN201080050285.XA patent/CN102762569B/zh not_active Expired - Fee Related
- 2010-08-06 WO PCT/EP2010/061518 patent/WO2011054553A1/en active Application Filing
- 2010-08-06 PT PT107406548T patent/PT2496580E/pt unknown
- 2010-08-06 NZ NZ599258A patent/NZ599258A/en not_active IP Right Cessation
- 2010-08-06 PT PT131926669T patent/PT2722334E/pt unknown
- 2010-08-06 BR BR112012010706A patent/BR112012010706A2/pt active Search and Examination
- 2010-08-06 EP EP16150637.3A patent/EP3037423B1/en active Active
- 2010-08-06 PL PL13192666T patent/PL2722334T3/pl unknown
- 2010-08-06 ES ES16150637.3T patent/ES2652304T3/es active Active
- 2010-08-06 RS RS20140088A patent/RS53179B/en unknown
- 2010-08-06 DK DK13192666.9T patent/DK2722334T3/en active
- 2010-08-06 JP JP2012537329A patent/JP5524343B2/ja active Active
- 2010-08-06 AU AU2010314395A patent/AU2010314395B2/en not_active Ceased
- 2010-08-06 ES ES13192666.9T patent/ES2563057T3/es active Active
- 2010-08-06 ES ES10740654.8T patent/ES2446647T3/es active Active
- 2010-08-06 ME MEP-2016-53A patent/ME02360B/me unknown
- 2010-08-06 CA CA2779355A patent/CA2779355C/en not_active Expired - Fee Related
- 2010-08-06 US US13/505,039 patent/US9023842B2/en active Active
- 2010-08-06 PE PE2012000614A patent/PE20121181A1/es not_active Application Discontinuation
- 2010-08-06 DK DK10740654.8T patent/DK2496580T3/da active
- 2010-08-06 MX MX2012005295A patent/MX2012005295A/es active IP Right Grant
- 2010-08-06 KR KR1020127014637A patent/KR101424989B1/ko active IP Right Grant
-
2012
- 2012-04-05 IL IL219090A patent/IL219090A0/en unknown
- 2012-04-18 DO DO2012000114A patent/DOP2012000114A/es unknown
- 2012-05-04 CL CL2012001178A patent/CL2012001178A1/es unknown
- 2012-05-10 CO CO12077201A patent/CO6540003A2/es unknown
- 2012-05-28 CR CR20120283A patent/CR20120283A/es unknown
- 2012-06-04 MA MA34934A patent/MA33803B1/fr unknown
-
2013
- 2013-02-21 HK HK14104251.0A patent/HK1191012A1/zh not_active IP Right Cessation
- 2013-02-21 HK HK13102225.8A patent/HK1175458A1/xx not_active IP Right Cessation
-
2014
- 2014-02-05 HR HRP20140107AT patent/HRP20140107T1/hr unknown
- 2014-02-18 CY CY20141100124T patent/CY1114988T1/el unknown
- 2014-02-20 SM SM201400024T patent/SMT201400024B/xx unknown
- 2014-11-30 IL IL235983A patent/IL235983B/en active IP Right Grant
-
2015
- 2015-04-13 US US14/684,659 patent/US20150210706A1/en not_active Abandoned
-
2016
- 2016-02-03 HR HRP20160119TT patent/HRP20160119T1/hr unknown
- 2016-03-01 CY CY20161100172T patent/CY1117479T1/el unknown
- 2016-03-22 SM SM201600081T patent/SMT201600081B/xx unknown
- 2016-07-13 HK HK16108220.7A patent/HK1220188A1/zh unknown
-
2017
- 2017-01-20 US US15/410,874 patent/US20170197972A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20120283A (es) | Inhibidor de bromodominio de benzodiazepina | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
SV2010003738A (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
ECSP088800A (es) | Formulaciones de inhibidores de DPP IV | |
ECSP099721A (es) | Inhibidores de cinasa p70 s6 | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
CR20140544A (es) | Compuestos para inhibir la progresión mitotica | |
UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
CU20110204A7 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
CR11618A (es) | Inhibidores macrocíclicos de serina proteasa | |
CR11861A (es) | Compuestos organicos | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
UY31922A (es) | Compuestos | |
GT200800251A (es) | Nitrilos espirociclicos como inhibidores de proteasa | |
UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
ECSP10010200A (es) | Derivados de pirazol como inhibidores de 5-lo | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
ECSP088464A (es) | Compuesto para la inhibición de la apoptosis | |
CL2012001759A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica. | |
UA105675C2 (uk) | Бензодіазепіновий інгібітор бромодомену | |
ECSP13012372A (es) | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. | |
NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa |